NAHRI Journal - Volume 3, Issue 2

A data analyst shares her experiences in denials prevention

Monday, April 1, 2019
Revenue Integrity

Get to know Tracey Tomak, RHIA, PMP.Read More »

NAHRI Journal - Volume 3, Issue 2

Hitting the mark: Defend against IRF audits and denials with coding and documentation improvements

Monday, April 1, 2019
Coding and Documentation, Compliance, Coverage, Denials and Appeals, Revenue Integrity

Use these expert tips to tighten up IRF compliance and avoid costly denials.Read More »

NAHRI Journal - Volume 3, Issue 2

Price transparency: Opportunities and threats

Monday, April 1, 2019
Chargemaster and Charge Capture, Compliance, Program Management, Revenue Integrity

Review the impact of the first months of CMS’ price transparency requirement and look ahead to the next steps.Read More »

NAHRI Journal - Volume 3, Issue 2

NAHRI welcomes new board and committee members

Monday, April 1, 2019

Welcome the new members of NAHRI’s Advisory Board and committees.Read More »

NAHRI Journal - Volume 3, Issue 2

Download the April 2019 issue of the NAHRI Journal

Monday, April 1, 2019
Revenue Integrity

Explore new revenue integrity frontiers with this issue of the NAHRI Journal.Read More »

NAHRI Journal - Volume 3, Issue 2

Vet documentation for IRF appeals

Monday, April 1, 2019
Coding and Documentation, Compliance, Coverage, Denials and Appeals, Revenue Integrity

Experts share insight on how to ensure inpatient rehabilitation facility documentation will stand up to an appeal.Read More »

2019 State of the Revenue Integrity Industry Survey

Thursday, March 28, 2019
Revenue Integrity

NAHRI is conducting its annual State of the Revenue Integrity Industry survey, and we want to hear about your revenue integrity experience.Read More »

Revenue Integrity Insider

April quarterly OPPS update affects pricing for skin substitute products, billing for CAR-T therapy

Wednesday, March 27, 2019
Billing and Claims, Coding and Documentation, Reimbursement and Payment Methodologies

The April 2019 OPPS quarterly update reassigned specific skin substitute products from the low-cost group to the high-cost group, and clarified billing and reporting for chimeric antigen receptor T-cell (CAR-T) therapy procedures performed in the outpatient setting.Read More »

Pages